November 16, 2026 — CanSino Biologics Inc. ("CanSinoBIO" or the "Company"; 688185.SH, 06185.HK) announced that it has received approval from China's National Medical Products Administration (NMPA) to conduct clinical trials of its Tetanus, Reduced Diphtheria and Pertussis (Acellular, Five Components) Combined Vaccine, Adsorbed (the "Td5cp") in people aged 4–5 years. This approval marks a further step toward expanding the vaccine's target age range and potentially strengthening protection against pertussis, diphtheria and tetanus in children.
CanSinoBIO's Td5cp is designed to provide booster immunization against pertussis, diphtheria and tetanus across different age groups. The vaccine candidate for individuals aged 6 years and older has been granted Priority Review status by the NMPA, and its New Drug Application (NDA) has been formally accepted for review.
Pertussis, also known as whooping cough, is a highly contagious respiratory infection caused by Bordetella pertussis. ¹ Vaccination is an essential measure for preventing the disease. However, vaccine-induced immunity may wane over time, ² highlighting the importance of timely booster immunization to maintain protection and reduce the risk of transmission as children grow older.
In international immunization practice, reduced-dose component-purified Tdap vaccines are generally used in place of full-dose co-purified DTaP vaccines for booster immunization starting at 4 years of age. With lower antigen content for pertussis and diphtheria, reduced-dose component-purified Tdap vaccines are associated with a lower incidence of adverse reactions, particularly as the number of doses and age at vaccination increase.
The newly approved clinical trial will evaluate Td5cp in children aged 4–5 years, extending its clinical development beyond the existing target population of individuals aged 6 years and older. Timely booster vaccination may help reactivate immune memory and increase antibody levels, potentially addressing gaps in protection before school entry and providing an additional means of reducing pertussis transmission risks in preschools and primary schools.
CanSinoBIO is advancing its portfolio of innovative pertussis-containing combination vaccines, covering primary immunization in infants and booster immunization for children, adolescents and adults. With the approval of Tripecia®, its three-component DT3cP vaccine for infants, and the ongoing clinical development and regulatory review of Td5cp, the Company is steadily expanding its vaccine offerings across different age groups.
Building on these developments, CanSinoBIO remains committed to advancing innovative vaccine R&D and clinical development to address immunization needs throughout the life course, bringing more disease prevention options to populations worldwide.
References
1. Chinese Center for Disease Control and Prevention. Disease Overview: Pertussis [EB/OL]. (2026-06-22) [Accessed 2026-11-16].
https://www.chinacdc.cn/jkyj/mygh02/ymkyfjb/brk/202606/t20260622_1837271.html.
2. National Health Commission of the People's Republic of China. Guidelines for the Diagnosis and Treatment of Pertussis (2023 Edition) [EB/OL]. [Accessed 2026-11-16].
https://www.nhc.gov.cn/ylyjs/gzdt/202312/7553bd72c9934f4ca72327b361d111be/files/1734003068417_92469.pdf.
Relevant News
CanSinoBIO's Td5cp Vaccine for Adolescents and Adults NDA Accepted by China's NMPA
Disclaimer:
Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.